鹰架技术市场 - 全球产业规模、份额、趋势、机会及预测（按类型、疾病类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球鹰架技术市场预计将从 2025 年的 22.2 亿美元成长到 2031 年的 35.2 亿美元，复合年增长率为 7.99%。

支架技术能够建构多孔的三维结构，模拟天然细胞外基质，为再生医学和组织工程中的细胞黏附、增殖和分化提供基础。推动这项技术发展的关键因素包括供体器官的严重短缺，以及日益增长的减少药物研发中动物试验的伦理和监管要求，这两方面都促使人们迫切需要有效的生物替代物。美国卫生资源与服务管理局 (HRSA) 的报告凸显了这一紧迫性：到 2024 年，美国国家移植等待名单上的候选人将超过 10.3 万人，这表明生物工程组织替代品在商业性和临床方面有着巨大的需求。

儘管市场成长前景良好，但仍面临一项重大挑战：支架製造和材料表征缺乏标准化。生物材料固有的天然变异性，加上难以在商业规模上持续复製其复杂的微观结构，使得批次间一致性难以保证。缺乏成熟的製造通讯协定阻碍了监管核准流程，并延缓了基于支架的创新成果从实验室走向广泛临床应用的进程。

市场驱动因素

3D生物列印和生物材料的创新正在改变全球支架技术市场，使建造先前无法实现的复杂、大规模组织结构成为可能。先进生物墨水与高解析度列印系统的结合，能够精准定位细胞和基质成分，有效解决厚组织血管化难题。 2024年6月，CollPlant Biotechnologies宣布利用其专有的重组人类胶原蛋白生物墨水生产出200cc商业规模的再生乳房植入，这一重大突破意义非凡。该成就表明，该行业从实验性微组织到临床应用器官类似物的规模化生产能力日益增强，加速了基于支架的塑胶重组和治疗解决方案的研发进程。

同时，研发投入的不断增加正成为推动这些技术走向临床应用的资金引擎。来自公共和私营部门的资金日益集中于那些利用支架平台满足高度未满足医疗需求的公司，例如癌症治疗和神经退化性疾病。加州再生医学研究所2024年度报告凸显了这一领域的强劲势头，报告指出，Neurona Therapeutics公司筹集了1.2亿美元，用于推进依赖复杂递送系统的细胞疗法。这笔资金的涌入主要是为了因应慢性疾病的日益增加。例如，美国癌症协会在2024年1月预测，美国新增癌症病例数将首次超过200万，促使投资人加强对能够改善疾病建模和组织修復的支架解决方案的支持。

市场挑战

支架製造和材料表征缺乏标准化通讯协定，严重阻碍了全球支架技术市场的发展。这个问题源自于生物材料固有的变异性以及大规模复製精确微观结构的技术复杂性。因此，製造商难以确保批次间的一致性，也难以建立大规模生产所需的统一流程。由于缺乏标准化方法，企业在将成功的实验室原型转化为商业性化产品的过程中面临瓶颈，导致供应链停滞，而临床上对组织替代的需求却十分迫切。

这种异质性直接阻碍了监管核准和市场准入，因为监管机构要求提供严格的可重复性证明以确保病人安全。无法证明生产结果的一致性会导致商业化进程显着延迟，并限制已通过核准治疗方法的广泛应用。因此，规模化生产的困难阻碍了大多数创新在临床实践中的广泛应用。再生医学联盟报告称，到2025年，全球先进疗法领域75%的收入将由不到10种产品创造。这种高度的收入集中度凸显了生产壁垒和缺乏标准化如何持续限制整体市场成长潜力。

市场趋势

将人工智慧 (AI) 应用于支架设计正在革新整个产业，因为它能够开发出更符合生理规律的生物结构。与传统方法不同，AI 演算法可以在生产前预测细胞与材料的相互作用并优化内部孔隙率，从而显着减少组织工程中的试验。 Aspect Biosystems 公司成功完成资金筹措，进一步开发其模式识别技术，凸显了这种计算方法的价值。正如该公司在 2025 年 1 月的新闻稿中所述，该公司在 B 轮资金筹措中筹集了 1.15 亿美元，用于扩展其平台。该平台利用 AI 驱动的设计工具来创建生物列印组织疗法。

同时，对能够最大限度减少免疫排斥并促进自然重塑的构建体的需求日益增长，促使脱细胞细胞外基质（dECM）生物支架作为合成聚合物的更优替代品得到广泛应用。这些生物支架保留了触发细胞讯号传导的天然生化讯号，从而促进与宿主的快速整合。这一趋势最终促成了美国食品药物管理局（FDA）于2024年12月核准Humacyte公司的Symvess上市，这标誌着无细胞组织商业性可行性的一个重要监管里程碑。这种基于dECM的血管移植物核准，代表着生物工程人体组织临床应用的突破。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球鹰架技术市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（水凝胶{创伤治疗、3D生物列印、免疫调节}、聚合物支架、微图案化表面微孔盘、奈米纤维支架）
  • 依疾病类型（整形外科、肌肉骨骼和脊椎、癌症、皮肤和覆盖组织、牙科、心血管、神经科、泌尿系统、妇科、其他）
  • 依应用领域（干细胞疗法、再生医学/组织工程、药物研发等）
  • 依最终用户（生技/製药公司、研究机构、医院/诊断中心等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美鹰架技术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲脚手架技术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区鹰架技术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲鹰架技术市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲鹰架技术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球鹰架技术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Tecan Group Ltd.
• REPROCELL Inc.
• 3D Biotek, LLC
• Becton, Dickinson, and Company
• Medtronic plc
• Xanofi, Inc.
• Molecular Matrix, Inc.
• Matricel GmbH
• PELOBiotech GmbH
• Corning Incorporated

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Scaffold Technology Market is projected to expand from USD 2.22 Billion in 2025 to USD 3.52 Billion by 2031, registering a CAGR of 7.99%. Scaffold technology involves the creation of porous three-dimensional structures that simulate the natural extracellular matrix, acting as a template to facilitate cell adhesion, proliferation, and differentiation for regenerative medicine and tissue engineering. The primary catalysts for this growth include the severe shortage of donor organs and increasing ethical and regulatory mandates to reduce animal testing in drug development, both of which drive the need for effective biological substitutes. Highlighting this urgency, the Health Resources and Services Administration reported in 2024 that over 103,000 candidates were on the U.S. national transplant waiting list, emphasizing the critical commercial and clinical demand for bioengineered tissue alternatives.

Despite this positive growth outlook, the market contends with a major hurdle regarding the absence of standardization in scaffold manufacturing and material characterization. The natural variability inherent in biological materials, combined with the difficulty of consistently replicating intricate micro-architectures at a commercial scale, creates challenges in maintaining batch-to-batch uniformity. This lack of established manufacturing protocols hinders the regulatory approval pathway and delays the progression of scaffold-based innovations from research laboratories to widespread clinical application.

Market Driver

Innovations in 3D Bioprinting and Biomaterials are transforming the Global Scaffold Technology Market by allowing for the creation of complex, large-scale tissue constructs that were previously unachievable. The combination of advanced bioinks with high-resolution printing systems enables the precise placement of cells and matrix components, effectively solving the issue of vascularization in thick tissues. A significant breakthrough was marked in June 2024 when CollPlant Biotechnologies announced the production of 200cc commercial-scale regenerative breast implants using its proprietary recombinant human collagen bioinks. This achievement highlights the industry's growing capacity to scale up from experimental micro-tissues to clinically relevant organ analogues, accelerating the timeline for scaffold-based reconstructive and therapeutic solutions.

Simultaneously, rising investments in research and development act as the financial engine driving these technologies toward clinical use. Funding from both public and private sectors is increasingly targeted at companies employing scaffold platforms to address high unmet medical needs, such as oncology and neurodegenerative diseases. The sector's robustness was highlighted in the California Institute for Regenerative Medicine's 2024 Annual Report, which noted that Neurona Therapeutics raised $120 million to further cell therapies dependent on complex delivery systems. This influx of capital is largely a response to the growing prevalence of chronic diseases; for instance, the American Cancer Society projected in January 2024 that new cancer diagnoses in the U.S. would exceed 2 million for the first time, prompting investors to support scaffold solutions that offer improved disease modeling and tissue repair.

Market Challenge

The absence of standardized protocols for scaffold fabrication and material characterization poses a significant barrier to the growth of the Global Scaffold Technology Market. This issue stems from the inherent variability of biological materials and the technical complexity involved in reproducing precise micro-architectures at a commercial scale. As a result, manufacturers struggle to guarantee batch-to-batch consistency, making it difficult to establish the uniform processes required for mass production. Without these standardized methods, companies face a bottleneck in transitioning successful laboratory prototypes into commercially viable products, stalling the supply chain despite the pressing clinical need for tissue replacements.

This inconsistency directly impedes regulatory approval and market access, as agencies demand rigorous proof of reproducibility to ensure patient safety. The inability to demonstrate consistent manufacturing results causes significant delays in commercialization and restricts the availability of approved therapies. Consequently, scaling difficulties prevent most innovations from reaching widespread clinical adoption. In 2025, the Alliance for Regenerative Medicine reported that 75 percent of global revenue in the advanced therapy sector is generated by fewer than 10 products. This high concentration of revenue underscores how manufacturing hurdles and the lack of standardization continue to limit the broader market from realizing its full growth potential.

Market Trends

The incorporation of Artificial Intelligence into scaffold structural design is revolutionizing the industry by enabling the development of bio-architectures with greater physiological accuracy. Unlike conventional methods, AI algorithms can now predict cell-material interactions and optimize internal porosities prior to production, drastically reducing trial-and-error in tissue engineering. The value of this computational approach was confirmed when Aspect Biosystems secured significant funding to further its pattern-recognition technologies. As detailed in a January 2025 press release, the company raised $115 million in Series B financing to expand its platform, which utilizes AI-driven design tools for creating bioprinted tissue therapeutics.

Concurrently, there is a growing shift toward using Decellularized Extracellular Matrix (dECM) bio-scaffolds as a superior alternative to synthetic polymers, driven by the need for constructs that minimize immune rejection and support natural remodeling. These biological scaffolds preserve native biochemical cues that trigger cellular signaling, facilitating faster integration with the host body. This trend achieved a major regulatory milestone regarding the commercial viability of acellular tissues when the U.S. Food and Drug Administration approved Humacyte's Symvess in December 2024. This approval of a dECM-based vascular conduit represents a pivotal advancement in the clinical application of bioengineered human tissues.

Key Market Players

• Tecan Group Ltd.
• REPROCELL Inc.
• 3D Biotek, LLC
• Becton, Dickinson, and Company
• Medtronic plc
• Xanofi, Inc.
• Molecular Matrix, Inc.
• Matricel GmbH
• PELOBiotech GmbH
• Corning Incorporated

Report Scope

In this report, the Global Scaffold Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Scaffold Technology Market, By Type

• Hydrogels {Wound Healing, 3D Bioprinting, Immunomodulation}
• Polymeric Scaffolds
• Micropatterned Surface Microplates
• Nanofiber Based Scaffolds

Scaffold Technology Market, By Disease Type

• Orthopedics
• Musculoskeletal & Spine
• Cancer
• Skin & Integumentary
• Dental
• Cardiology & Vascular
• Neurology
• Urology
• Gynecology
• Others

Scaffold Technology Market, By Application

• Stem Cell Therapy
• Regenerative Medicine & Tissue Engineering
• Drug Discovery
• Others

Scaffold Technology Market, By End User

• Biotechnology & Pharmaceuticals Organizations
• Research Laboratories & Institutes
• Hospitals & Diagnostic Centers
• Others

Scaffold Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Scaffold Technology Market.

Available Customizations:

Global Scaffold Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Scaffold Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Hydrogels {Wound Healing, 3D Bioprinting, Immunomodulation}, Polymeric Scaffolds, Micropatterned Surface Microplates, Nanofiber Based Scaffolds)
  • 5.2.2. By Disease Type (Orthopedics, Musculoskeletal & Spine, Cancer, Skin & Integumentary, Dental, Cardiology & Vascular, Neurology, Urology, Gynecology, Others)
  • 5.2.3. By Application (Stem Cell Therapy, Regenerative Medicine & Tissue Engineering, Drug Discovery, Others)
  • 5.2.4. By End User (Biotechnology & Pharmaceuticals Organizations, Research Laboratories & Institutes, Hospitals & Diagnostic Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Scaffold Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Scaffold Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Scaffold Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Scaffold Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Scaffold Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Scaffold Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Scaffold Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Scaffold Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Scaffold Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Scaffold Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Scaffold Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Scaffold Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Scaffold Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Scaffold Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Scaffold Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Scaffold Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Scaffold Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Scaffold Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Scaffold Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Scaffold Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Scaffold Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Scaffold Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Scaffold Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Scaffold Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Scaffold Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Tecan Group Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. REPROCELL Inc.
• 15.3. 3D Biotek, LLC
• 15.4. Becton, Dickinson, and Company
• 15.5. Medtronic plc
• 15.6. Xanofi, Inc.
• 15.7. Molecular Matrix, Inc.
• 15.8. Matricel GmbH
• 15.9. PELOBiotech GmbH
• 15.10. Corning Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer